Alaunos Therapeutics (TCRT) Other Non-Current Assets (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Other Non-Current Assets came in at $831000.0 in Q1 2026, down 21.08% YoY from $1.1 million in Q1 2025, and down 6.31% on a QoQ basis from $887000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 17 years of Other Non-Current Assets data on file, last reported at $831000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 21.08% year-over-year to $831000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $831000.0 (down 21.08% YoY) and the FY2025 annual result came in at $887000.0, changed N/A from the prior year.
- Other Non-Current Assets retreated to $831000.0 in Q1 2026, from $887000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q1 2025 to a low of $1000.0 in Q2 2023.
- A 4-year average of $667000.0 and a median of $626000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 3025.0% — and 2023, when it slumped 99.8%.
- Tracing TCRT's Other Non-Current Assets over 4 years: stood at $500000.0 in 2022, then tumbled by 99.8% to $1000.0 in 2023, then soared by 88600.0% to $887000.0 in 2025, then retreated by 6.31% to $831000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $831000.0 (Q1 2026), $887000.0 (Q4 2025), and $942000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 776,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 831,000.00 |
| Dec 31, 2025 | 887,000.00 |
| Sep 30, 2025 | 942,000.00 |
| Jun 30, 2025 | 997,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 626,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 365,000.00 |
| Jun 30, 2021 | 16,000.00 |
| Mar 31, 2021 | 130,000.00 |
| Dec 31, 2020 | 130,000.00 |
| Sep 30, 2020 | 746,000.00 |
| Jun 30, 2020 | 130,000.00 |
| Mar 31, 2020 | 666,000.00 |
| Dec 31, 2019 | 110,000.00 |